Benign and Malignant Neoplasms of the Head and Neck

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 934

Special Issue Editors


E-Mail Website
Guest Editor
Department of Otolaryngology-Head and Neck Surgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA
Interests: sinonasal and skull base tumor; inverted papilloma; squamous cell carcinoma

E-Mail Website
Guest Editor
Department of Otolaryngology-Head and Neck Surgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA
Interests: head and neck cancer; HPV; salivary gland tumors; base of tongue cancer; robotic surgery

Special Issue Information

Dear Colleagues,

Head and neck tumors are a diverse group of neoplasms that present significant diagnostic and therapeutic challenges. This Special Issue focuses on benign and malignant head and neck tumors, exploring their pathogenesis, novel treatment options, specific biomarkers and therapeutic targets to improve diagnostics and treatment. 

This Special Issue will cover various topics relating head and neck neoplasms. We welcome submissions on the following subtopics: 

  • Research outcomes in disease control and overall survival in head and neck tumors;
  • Novel surgical techniques;
  • Novel biomarkers and potential therapeutic targets;
  • Advances in diagnostic tools, imaging protocols, AR/VR-assisted surgical planning;
  • Quality of life outcomes (cosmesis, voice, swallowing and hearing preservation).

Other topics within the scope of the issue will also be considered. We look forward to your contributions. 

Dr. Charles C. L. Tong
Dr. Brett A. Miles
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • laryngeal cancer
  • oral cavity and oropharynx cancer
  • nasal cavity and paransal sinus cancer
  • anterior and lateral skull base cancer
  • salivary gland cancer
  • melanoma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

19 pages, 8018 KiB  
Article
Morphological and Immunohistochemical Aspects with Prognostic Implications and Therapeutic Targets of Primary Sinonasal Mucosal Melanoma: A Retrospective Study
by Cornelia Marina Trandafir, Raluca Maria Closca, Marioara Poenaru, Oana Silvana Sarau, Cristian Andrei Sarau, Marina Rakitovan, Flavia Baderca and Laurentiu Vasile Sima
Cancers 2024, 16(16), 2863; https://doi.org/10.3390/cancers16162863 - 16 Aug 2024
Viewed by 592
Abstract
Sinonasal mucosal melanoma originates from melanocytes and it is a rare malignancy in the sinonasal tract. It is an aggressive melanocytic neoplasm with a very poor prognosis. The symptoms are nonspecific and the diagnosis is delayed, usually until the advanced stages of the [...] Read more.
Sinonasal mucosal melanoma originates from melanocytes and it is a rare malignancy in the sinonasal tract. It is an aggressive melanocytic neoplasm with a very poor prognosis. The symptoms are nonspecific and the diagnosis is delayed, usually until the advanced stages of the disease. The current study performs a correlation between the histopathological aspects of sinonasal mucosal melanoma and different types of immune cells present in the microenvironment, with prognostic and therapeutic implications. The endpoint is to quantify the cellular immune microenvironment and correlate it with patient survival. This study presents nine cases of primary sinonasal mucosal melanomas diagnosed at the Emergency City Hospital Timisoara, Romania during a period of 15 years. The histopathological examination was performed in the Department of Pathology of the same hospital, using morphological hematoxylin–eosin staining. Additional immunohistochemical reactions were performed to confirm the diagnosis and evaluate the components of the tumor immune microenvironment. This study identifies eosinophils, macrophages, natural killer cells and plasma cells as favorable prognostic factors. Therefore, a CD8:CD4 ratio of more than 3 is correlated with a good response to PD-1 inhibitor therapy. Full article
(This article belongs to the Special Issue Benign and Malignant Neoplasms of the Head and Neck)
Show Figures

Figure 1

Back to TopTop